These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 38549399)
21. Inclisiran for the treatment of cardiovascular disease: the ORION clinical development program. Stoekenbroek RM; Kallend D; Wijngaard PL; Kastelein JJ Future Cardiol; 2018 Nov; 14(6):433-442. PubMed ID: 30375244 [TBL] [Abstract][Full Text] [Related]
22. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. Raal FJ; Kallend D; Ray KK; Turner T; Koenig W; Wright RS; Wijngaard PLJ; Curcio D; Jaros MJ; Leiter LA; Kastelein JJP; N Engl J Med; 2020 Apr; 382(16):1520-1530. PubMed ID: 32197277 [TBL] [Abstract][Full Text] [Related]
23. The clinical effects of inclisiran, a first-in-class LDL-C lowering siRNA therapy, on the LDL-C levels in Chinese patients with hypercholesterolemia. Luo Z; Huang Z; Sun F; Guo F; Wang Y; Kao S; Yang G; Huang J; Li J; Zhao S; He Y J Clin Lipidol; 2023; 17(3):392-400. PubMed ID: 37164838 [TBL] [Abstract][Full Text] [Related]
24. Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran). Sinning D; Landmesser U Curr Cardiol Rep; 2020 Oct; 22(12):176. PubMed ID: 33089390 [TBL] [Abstract][Full Text] [Related]
31. Small Interfering RNA Therapeutic Inclisiran: A New Approach to Targeting PCSK9. German CA; Shapiro MD BioDrugs; 2020 Feb; 34(1):1-9. PubMed ID: 31782112 [TBL] [Abstract][Full Text] [Related]
32. The Effects of Statins, Ezetimibe, PCSK9-Inhibitors, Inclisiran, and Icosapent Ethyl on Platelet Function. Di Costanzo A; Indolfi C; Sorrentino S; Esposito G; Spaccarotella CAM Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511498 [TBL] [Abstract][Full Text] [Related]
33. Small Interfering Ribonucleic Acid as Lipid-Lowering Therapy: Inclisiran in Focus. Rakocevic J; Dobric M; Vucic R; Furtula M; Zaletel I; Milutinovic K; Ilijevski A; Borovic ML; Tomasevic M; Bajcetic M Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36983086 [TBL] [Abstract][Full Text] [Related]
34. Inclisiran: A Novel Small Interfering RNA Drug for Low-Density Lipoprotein Reduction. Smith KW; White CM J Clin Pharmacol; 2022 Sep; 62(9):1079-1085. PubMed ID: 35279835 [TBL] [Abstract][Full Text] [Related]
35. PCSK9 inhibition and atherosclerotic cardiovascular disease prevention: does reality match the hype? Hadjiphilippou S; Ray KK Heart; 2017 Nov; 103(21):1670-1679. PubMed ID: 28596304 [TBL] [Abstract][Full Text] [Related]
36. Inclisiran: A New Strategy for LDL-C Lowering and Prevention of Atherosclerotic Cardiovascular Disease. Albosta MS; Grant JK; Taub P; Blumenthal RS; Martin SS; Michos ED Vasc Health Risk Manag; 2023; 19():421-431. PubMed ID: 37434791 [TBL] [Abstract][Full Text] [Related]
37. Effect of inclisiran on lipids in primary prevention: the ORION-11 trial. Ray KK; Kallend D; Leiter LA; Raal FJ; Koenig W; Jaros MJ; Schwartz GG; Landmesser U; Garcia Conde L; Wright RS; Eur Heart J; 2022 Dec; 43(48):5047-5057. PubMed ID: 36331315 [TBL] [Abstract][Full Text] [Related]
38. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons. Yadav K; Sharma M; Ferdinand KC Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986 [TBL] [Abstract][Full Text] [Related]
39. Inclisiran siRNA technology in the management of dyslipidemia: A narrative review of clinical trials. Olatunji G; Kokori E; Yusuf IA; Akinmoju O; Egbunu E; Muogbo I; Lema K; Kanagala SG; Owolabi S; Abdulbasit M; Aderinto N Curr Probl Cardiol; 2024 Apr; 49(4):102419. PubMed ID: 38246315 [TBL] [Abstract][Full Text] [Related]
40. Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial. Leiter LA; Teoh H; Kallend D; Wright RS; Landmesser U; Wijngaard PLJ; Kastelein JJP; Ray KK Diabetes Care; 2019 Jan; 42(1):173-176. PubMed ID: 30487231 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]